These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 21592477

  • 1. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases.
    Corrao G, Scotti L, Zambon A, Baio G, Nicotra F, Conti V, Capri S, Tragni E, Merlino L, Catapano AL, Mancia G.
    Atherosclerosis; 2011 Aug; 217(2):479-85. PubMed ID: 21592477
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G, Conti V, Merlino L, Catapano AL, Mancia G.
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
    de Vries FM, Denig P, Visser ST, Hak E, Postma MJ.
    Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis.
    Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, Buda S, Degli Esposti E.
    Clin Ther; 2012 Jan; 34(1):190-9. PubMed ID: 22284998
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Jan; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T.
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [Abstract] [Full Text] [Related]

  • 11. Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland.
    Rannanheimo PK, Tiittanen P, Hartikainen J, Helin-Salmivaara A, Huupponen R, Vahtera J, Korhonen MJ.
    Value Health; 2015 Sep; 18(6):896-905. PubMed ID: 26409618
    [Abstract] [Full Text] [Related]

  • 12. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L, Teng M, Zhao YJ, Khoo AL, Seet RC, Yong QW, Yeo TC, Lim BP.
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [Abstract] [Full Text] [Related]

  • 13. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP, Visseren FL, de Wit GA, Algra A.
    BMJ; 2011 Mar 30; 342():d1672. PubMed ID: 21450800
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V, Nash A, Barry M.
    Ir Med J; 2006 May 30; 99(5):144-5. PubMed ID: 16892920
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.
    Aarnio E, Korhonen MJ, Huupponen R, Martikainen J.
    Atherosclerosis; 2015 Mar 30; 239(1):240-7. PubMed ID: 25618032
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA.
    JAMA; 2015 Jul 14; 314(2):142-50. PubMed ID: 26172894
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of the impact of the recent controversy over statins in France: the EVANS study.
    Saib A, Sabbah L, Perdrix L, Blanchard D, Danchin N, Puymirat E.
    Arch Cardiovasc Dis; 2013 Oct 14; 106(10):511-6. PubMed ID: 24080324
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.